High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group.

Abstract

The clinical efficacy of high dose (160 mg) polyoestradiol phosphate (PEP) was compared with that of orchiectomy in a prospective randomised multicentre study including 200 prostatic cancer patients. The effect of daily low dose (75 mg) acetosalicylic acid (ASA) on possible cardiovascular complications during the first 6 months of therapy was also evaluated. Oestrogen-treated patients had more progressions, but follow-up was too short to draw any definite conclusions on the efficacy of treatment. There was no cardiovascular mortality and there were no thromboembolic complications in any treatment group. It was concluded that parenteral high dose PEP is not associated with an increased risk of cardiovascular complications and there is no need for daily low dose ASA.

• Authors: J L Aro, R K Haapiainen, S A Rannikko, O S Alfthan
• Journal: British journal of urology (Br J Urol) Vol. 63 Issue 5 Pg. 512-4 (May 1989) ISSN: 0007-1331 [Print] England
• PMID: 2659136 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Estradiol Congeners
• Estradiol
• polyestradiol phosphate
• Aspirin

Topics

• Aged
• Aspirin (therapeutic use)
• Cardiovascular Diseases (chemically induced, prevention & control)
• Estradiol (adverse effects, analogs & derivatives, therapeutic use)
• Estradiol Congeners (adverse effects, therapeutic use)
• Follow-Up Studies
• Humans
• Male
• Middle Aged
• Multicenter Studies as Topic
• Orchiectomy
• Prospective Studies
• Prostatic Neoplasms (drug therapy, surgery, therapy)
• Random Allocation
• Risk